Enterprise Value
26.52M
Cash
4.904M
Avg Qtr Burn
-7.292M
Short % of Float
3.81%
Insider Ownership
0.68%
Institutional Own.
43.97%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELX-02 Details Rare genetic disease, Alport Syndrome | Phase 3 Initiation | |
ZKN-013 Details Rare genetic disease, Junctional epidermolysis bullosa, Recessive dystrophic epidermolysis bullosa | Phase 1 Initiation | |
ELX-02 Details Rare genetic disease | Failed Discontinued | |
ELX-02 Details Cystic fibrosis, Lung disease, Glabellar lines | Failed Discontinued |